Où achat cialis sans ordonnance et acheter viagra en France.

Microsoft word - foi 080 response 29.08.13.doc

FOI 1314 080
Summary Issue – ACEI Prescribing Policy
This information relates to Bristol Clinical Commissioning Group

Question
Response
Please provide any documents / information which Please note that records for the time period requested may be incomplete. Note also indicates whether Bristol Teaching PCT had any that Bristol PCT was formed in 2006 from a merger of Bristol North PCT and Bristol particular policy in place in relation to the prescribing South &West PCT so we have attempted to access the files from these other of Angiotensin-Converting Enzyme Inhibitors (ACEIs) organisations for the relevant time period. In earlier years paper records would have for the period 2004-2009. In particular, please provide been used much more than now, and these are no longer available. any prescribing recommendations / guidance / drug formularies encouraging a switch from perindopril to We can be certain however that ACE inhibitor (ACEI) prescribing was influenced and ramipril, lisinopril, enalapril or any other ACEI or incentivised at points in the time period that you have specified. The NHS ‘Better encouraging the prescription of low cost ACEIs (e.g. Care, Better Value’ national agenda encouraged the prescribing of ACEI in ramipril, lisinopril, enalapril) in place of more preference to Angiotensin 2 receptor antagonists (A2RA) wherever possible, and this was reflected in local formularies and prescribing incentive schemes (see below). We
can see that the choice of ramipril and lisinopril as preferred ACEI was specifically
encouraged and incentivised, and certainly prescribing of perindopril was
discouraged owing to its prohibitive acquisition cost to the NHS, and its non-superior
evidence base at the time.
2004/2005
The Bristol North PCT prescribing incentive scheme did not appear to incentivise any
particular activity in relation to ACEI prescribing and no record of any relevant ad-hoc
projects can be found.

No records exist of any prescribing incentive scheme for Bristol South & West PCT
and no record of any relevant ad-hoc projects can be found.
2005/2006

The Bristol North PCT prescribing incentive scheme did not appear to incentivise any
particular activity in relation to ACEI prescribing and no record of any relevant ad-hoc
projects can be found.
The Bristol South & West PCT prescribing incentive scheme did not appear to
incentivise any particular activity in relation to ACEI prescribing and no record of any
relevant ad-hoc projects can be found.
2006/2007

The Bristol North PCT prescribing incentive scheme included an audit to assess
compliance with NICE guidance but did not appear to incentivise any particular
activity in relation to ACEI prescribing and no record of any relevant ad-hoc projects
can be found.
The Bristol South & West PCT prescribing incentive scheme did not appear to
incentivise any particular activity in relation to ACEI prescribing and no record of any
relevant ad-hoc projects can be found.
2007/2008
The Bristol PCT prescribing incentive scheme did not appear to incentivise any
particular activity in relation to ACEI prescribing and no record of any relevant ad-hoc
projects can be found.

2008/2009
The Bristol PCT prescribing incentive scheme did incentivise practices to increase the
proportion of ACEI prescribed as a proportion of all renin-angiotensin system (RAS)
prescribing, and also to decrease the proportion of ACEI prescribing that perindopril
represented.
(see extract A)
We have a copy of a Bristol PCT formulary on file that was produced in 2008. This
clearly discourages prescribing of perindopril and encourages the use of other ACEI.
(see extracts B to E)
We also have records that show that Bristol PCT used ScriptSwitch software to
encourage prescribing of preferred ACEI in in 2008 and 2009.
2009/2010
The Bristol PCT prescribing incentive scheme did not appear to incentivise any
particular activity in relation to ACEI prescribing but the behaviours encouraged in the
previous years’ work continued to be promoted on an ad-hoc basis, and via
ScriptSwitch.
The information provided in this response is accurate as of 08/08/2013.

Source: http://www.bristolccg.nhs.uk/media/26783/FOI%201314%20080%20response%2029.08.13.pdf

Johann.indd

Zur Komorbidität von Aufmerksamkeitsdefizit/Hyperaktivitätssyndrom (ADHS) und Substanzstörungen Monika JOHANN*, Kirsten LANGE**, Susanne KÖNIG***, Rainer LAUFKÖTTER****, Willi UNGLAUB*****, Norbert WODARZ****** ZusammenfassungDas komorbide Auftreten eines Aufmerksamkeitsdefizit-/Hyperaktivitätssyn- droms (ADHS) wurde bei bis zu 1/3 der erwachsenen Kokainabhängigen ge-funden

Http://www.fda.gov/safety/recalls/ucm210443.htm

McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Infants’ and . Home> Safety> Recalls, Market Withdrawals, & Safety Alerts Recall -- Firm Press Release FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product o

Copyright © 2010-2014 Pdf Medic Finder